As CEO Todd Zavodnick put it: A lot of patients are being undertreated and we believe this market is massive. #Biotech #AllergyInnovation #Immunology #LifeSciences #FundingNews To view or add a comment, sign in Improvement of the therapeutic management of allergic patients in Europe An expert think tank's position paper on allergen immunotherapy To view or add a comment, sign in Yuhan Corporation's novel allergy drug lesigercept gains IND approval from MFDS for Phase 2 clinical trials - 12-week treatment for 150 patients with chronic spontaneous urticaria - Study to confirm safety, efficacy, and clinical benefits in an expanded patient cohort in Asia and Europe Yuhan Corporation announced on October 15 that it received approval from the Ministry of Food and Drug Safety (MFDS) on October 14 for its Phase 2 clinical trial plan (IND) for lesigercept (development code YH35324). Lesigercept is a novel anti-Immunoglobulin E (IgE) Fc fusion protein drug designed to alleviate allergic symptoms through a dual mechanism of action, by binding to and eliminating both free IgE and IgE receptor alpha (FcRI) autoantibodies present in the bloodstream
Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo
For example, haemoglobin and myoglobin bind oxygen in the form of Fe 2 +, while catalase and peroxidase utilise Fe 3+ in redox reactions
The compound has gained significant attention for its potential effects on telomerase activity the enzyme responsible for maintaining telomere length in cells
What Are the Different Types of Acne
(Cham: Springer International Publishing), 193206
![product question] has anyone tried GHK-CU injections for skin care ( improving skin texture and reducing fine lines and wrinkles) and if so what were your results? My dermatologist suggested it but](https://i.redd.it/adeon28suh8f1.jpeg)
